Abstract

GARCIA-BUSTOS, Víctor; VICENTE ESPLUGUES-MOTA, Juan  and  MARTI-RODRIGO, Alberto. Human Immunodeficiency Virus-Hepatitis C virus coinfection: towards a new therapeutic scenario. Rev haban cienc méd [online]. 2017, vol.16, n.2, pp. 199-216. ISSN 1729-519X.

Introduction:Therapies for hepatitis C virus (HCV) have rapidly evolved with the development of direct-acting antiviral agents. New regimens, achieve an equate response rates to treatment in cases of HCV mono-infected and HIV/HCV co-infected; a population traditionally difficult to treat due to a high hepatic and systemic morbidity-mortality, adverse reactions and drug interactions. Objective: To analyse the current Pharma-therapeutic options available for co-infected HIV-HCV patients, with emphasis I the new direct-acting antiviral agents, in order to offer a useful tool for the therapeutic approach in these patients. Material and Methods: Original articles, clinical studies and systematic reviews until September 2016 were carried out, as well as international drug interactions databases and updated Practical Guidelines. Development: Therapies for hepatitis C virus (HCV) have rapidly evolved with the development of direct-acting antiviral agents. New regimens achieve an equate response rates to treatment in HCV mono-infected and HIV/HCV co-infected; a population traditionally difficult to treat, which also associate a high hepatic and systemic morbidity-mortality, adverse reactions and complex drug interactions. Conclusions: In this new scenario efforts must be addressed to identify the high percentage of undiagnosed patients; potential interactions, especially with drugs related with patient’s aging; medium and long-term adverse reactions and development of drug resistances, as well as to guarantee universal coverage in all clinical contexts.

Keywords : HIV/HCV coinfection; HIV/HCV treatment; Hepatitis C; HIV; Direct-acting antiviral agents; DAA.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )